Ye Qin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ye Qin has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Yinhong Song
Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, People’s Republic of China
2 shared publications Yiyu Wang
Hubei Key Laboratory of Natural Products Research and Development, College of Biological and Pharmaceutical Sciences, China Three Gorges University, Yichang 443002, China
2 shared publicationsYuan Mou
Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China
2 shared publications- Zhangshuang Deng
Hubei Key Laboratory of Natural Products Research and Development, College of Biological and Pharmaceutical Sciences, China Three Gorges University, Yichang 443002, China
2 shared publications Zhong He
Hubei Key Laboratory of Natural Products Research and Development, College of Biological and Pharmaceutical Sciences, China Three Gorges University, Yichang 443002, China; Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Sciences, China Three Gorges University, Yichang 443002, China; State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
2 shared publicationsCaijing Chen
Department of Neurology, Ningbo HwaMei Hospital, Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, China
1 shared publication
Latest Publications
- 23 April 2025
- Published by Elsevier in Fitoterapia
- Vol. 183, 106567
4, 9-dihydroxy-α-lapachone as a potent antiproliferation agent for triple-negative breast cancer via ferroptosis
- 23 April 2025
- Published by Elsevier in Fitoterapia
- Vol. 183, 106567
4, 9-dihydroxy-α-lapachone as a potent antiproliferation agent for triple-negative breast cancer via ferroptosis
- Open Access
- 7 July 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1214675
Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential
Lysine-specific demethylase 1 (LSD1) is an enzyme that removes lysine methylation marks from nucleosome histone tails and plays an important role in cancer initiation, progression, metastasis, and recurrence. Recent research shows that LSD1 regulates tumor cells and immune cells through multiple upstream and downstream pathways, enabling tumor cells to adapt to the tumor microenvironment (TME). As a potential anti-tumor treatment strategy, immunotherapy has developed rapidly in the past few years. However, most patients have a low response rate to available immune checkpoint inhibitors (ICIs), including anti-PD-(L)1 therapy and CAR-T cell therapy, due to a broad array of immunosuppressive mechanisms. Notably, inhibition of LSD1 turns “cold tumors” into “hot tumors” and subsequently enhances tumor cell sensitivity to ICIs. This review focuses on recent advances in LSD1 and tumor immunity and discusses a potential therapeutic strategy for combining LSD1 inhibition with immunotherapy.
- 7 July 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1214675
Open AccessTargeting LSD1 in tumor immunotherapy: rationale, challenges and potential
Lysine-specific demethylase 1 (LSD1) is an enzyme that removes lysine methylation marks from nucleosome histone tails and plays an important role in cancer initiation, progression, metastasis, and recurrence. Recent research shows that LSD1 regulates tumor cells and immune cells through multiple upstream and downstream pathways, enabling tumor cells to adapt to the tumor microenvironment (TME). As a potential anti-tumor treatment strategy, immunotherapy has developed rapidly in the past few years. However, most patients have a low response rate to available immune checkpoint inhibitors (ICIs), including anti-PD-(L)1 therapy and CAR-T cell therapy, due to a broad array of immunosuppressive mechanisms. Notably, inhibition of LSD1 turns “cold tumors” into “hot tumors” and subsequently enhances tumor cell sensitivity to ICIs. This review focuses on recent advances in LSD1 and tumor immunity and discusses a potential therapeutic strategy for combining LSD1 inhibition with immunotherapy.
- 22 January 2022
- Published by Springer Nature in Journal of Molecular Histology
- Vol. 53 (2) , 413-421
Knockdown of lncRNA HAGLR promotes Treg cell differentiation through increasing the RUNX3 level in dermatomyositis
Dermatomyositis (DM) is a systemic autoimmune disease. It’s known that the number of regulatory T (Treg) cells was decreased in DM. Besides, Treg cells were increased after treatment in DM patients. Forkhead box P3 (Foxp3) is specifically expressed in Treg cells and Runt-related transcription factor (RUNX3) could regulate Foxp3 transcription. And our previous experiment showed that Homeobox D gene cluster antisense growth-associated long noncoding RNA (HAGLR) was up-regulated in DM patients. Here, we aimed to explore whether HAGLR regulated the differentiation of Treg cells through RUNX3-mediated transcription of Foxp3, thus affecting the progression of DM. The levels of HAGLR, Foxp3, and RUNX3 were examined by quantitative real-time PCR. The protein levels of Foxp3 and RUNX3 were examined by western blot. The proportions of Treg cells in CD4+ T cells were detected by flow cytometry. Hematoxylin and eosin staining was conducted to observe the histopathological changes of the muscle. RNA pull-down assay was performed to detect the interaction between HAGLR and RUNX3. A dual-luciferase reporter gene assay was conducted to examine the effect of HAGLR on the transcriptional regulation of Foxp3 by RUNX3. HAGLR was up-regulated and Foxp3 was down-regulated in DM patients. Besides, RUNX3 protein levels were decreased in DM patients, while its mRNA levels did not change significantly. The proportion of Treg cells was down-regulated in DM patients. In addition, interference with HAGLR could increase the levels of Foxp3, RUNX3 protein level, and the proportion of Treg cells. Besides, there was an interaction between HAGLR and RUNX3. We also found that knockdown of HAGLR and RUNX3 restored the increased Treg cells induced by HAGLR knockdown alone. In vivo experiments indicated that injection with adv-HAGLR increased Treg cell proportion and attenuated DM development. Interference with HAGLR could increase the protein levels of RUNX3, high levels of RUNX3 further promoted the expression of the Foxp3, thus restoring the number of Treg cells and easing the development of DM.
- 22 January 2022
- Published by Springer Nature in Journal of Molecular Histology
- Vol. 53 (2) , 413-421
Knockdown of lncRNA HAGLR promotes Treg cell differentiation through increasing the RUNX3 level in dermatomyositis
Dermatomyositis (DM) is a systemic autoimmune disease. It’s known that the number of regulatory T (Treg) cells was decreased in DM. Besides, Treg cells were increased after treatment in DM patients. Forkhead box P3 (Foxp3) is specifically expressed in Treg cells and Runt-related transcription factor (RUNX3) could regulate Foxp3 transcription. And our previous experiment showed that Homeobox D gene cluster antisense growth-associated long noncoding RNA (HAGLR) was up-regulated in DM patients. Here, we aimed to explore whether HAGLR regulated the differentiation of Treg cells through RUNX3-mediated transcription of Foxp3, thus affecting the progression of DM. The levels of HAGLR, Foxp3, and RUNX3 were examined by quantitative real-time PCR. The protein levels of Foxp3 and RUNX3 were examined by western blot. The proportions of Treg cells in CD4+ T cells were detected by flow cytometry. Hematoxylin and eosin staining was conducted to observe the histopathological changes of the muscle. RNA pull-down assay was performed to detect the interaction between HAGLR and RUNX3. A dual-luciferase reporter gene assay was conducted to examine the effect of HAGLR on the transcriptional regulation of Foxp3 by RUNX3. HAGLR was up-regulated and Foxp3 was down-regulated in DM patients. Besides, RUNX3 protein levels were decreased in DM patients, while its mRNA levels did not change significantly. The proportion of Treg cells was down-regulated in DM patients. In addition, interference with HAGLR could increase the levels of Foxp3, RUNX3 protein level, and the proportion of Treg cells. Besides, there was an interaction between HAGLR and RUNX3. We also found that knockdown of HAGLR and RUNX3 restored the increased Treg cells induced by HAGLR knockdown alone. In vivo experiments indicated that injection with adv-HAGLR increased Treg cell proportion and attenuated DM development. Interference with HAGLR could increase the protein levels of RUNX3, high levels of RUNX3 further promoted the expression of the Foxp3, thus restoring the number of Treg cells and easing the development of DM.
- Open Access
- 9 December 2021
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2021, 1-18
KDM1A Identified as a Potential Oncogenic Driver and Prognostic Biomarker via Multi-Omics Analysis
Background. Lysine-specific demethylase 1A (KDM1A) is a histone demethylation enzyme and a crucial epigenetic factor for multiple pathological pathways that mediate carcinogenesis and immunogenicity. Although increasing evidence supposes the association between KDM1A and cancers, no systematic multi-omics analysis of KDM1A is available. Methods. We systematically evaluated the KDM1A expression of various cancer and normal tissues and the unique relationship between KDM1A expression and prognosis of cancer cases based on The Cancer Genome Atlas (TCGA), Genotype Tissue Expression (GTEx), and Clinical Proteomic Tumor Analysis Consortium (CPTAC) database. The genetic variations, phosphorylation, and DNA methylation of KDM1A were analyzed via various tools. We further analyzed the correlation of KDM1A expression and fibroblasts and immune cell infiltration score of TCGA samples via TIMER2.0. Results. KDM1A was highly expressed in 17 types of total 33 cancers, while it expressed low levels in only 4 cancers. High KDM1A expression was associated with worse survival status in various cancers. KDM1A expression was positively correlated with the cancer-associated fibroblasts and myeloid-derived suppressor cells infiltration levels in most cancer types. Additionally, KDM1A in most cancer types was negatively correlated with Th1 cell infiltration and positively correlated with Th2 cells. Moreover, spliceosome, cell cycle, and RNA transport pathways were involved in the functional mechanisms of KDM1A via enrichment analysis. Conclusions. Our study describes the epigenetic factor KDM1A as an oncogene and prognostic biomarker. Our findings provide valuable guidance for further analysis of KDM1A function in pathogenesis and potential clinical treatment.
- 9 December 2021
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2021, 1-18
Open AccessKDM1A Identified as a Potential Oncogenic Driver and Prognostic Biomarker via Multi-Omics Analysis
Background. Lysine-specific demethylase 1A (KDM1A) is a histone demethylation enzyme and a crucial epigenetic factor for multiple pathological pathways that mediate carcinogenesis and immunogenicity. Although increasing evidence supposes the association between KDM1A and cancers, no systematic multi-omics analysis of KDM1A is available. Methods. We systematically evaluated the KDM1A expression of various cancer and normal tissues and the unique relationship between KDM1A expression and prognosis of cancer cases based on The Cancer Genome Atlas (TCGA), Genotype Tissue Expression (GTEx), and Clinical Proteomic Tumor Analysis Consortium (CPTAC) database. The genetic variations, phosphorylation, and DNA methylation of KDM1A were analyzed via various tools. We further analyzed the correlation of KDM1A expression and fibroblasts and immune cell infiltration score of TCGA samples via TIMER2.0. Results. KDM1A was highly expressed in 17 types of total 33 cancers, while it expressed low levels in only 4 cancers. High KDM1A expression was associated with worse survival status in various cancers. KDM1A expression was positively correlated with the cancer-associated fibroblasts and myeloid-derived suppressor cells infiltration levels in most cancer types. Additionally, KDM1A in most cancer types was negatively correlated with Th1 cell infiltration and positively correlated with Th2 cells. Moreover, spliceosome, cell cycle, and RNA transport pathways were involved in the functional mechanisms of KDM1A via enrichment analysis. Conclusions. Our study describes the epigenetic factor KDM1A as an oncogene and prognostic biomarker. Our findings provide valuable guidance for further analysis of KDM1A function in pathogenesis and potential clinical treatment.
- Open Access
- 30 November 2018
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
- Vol. 51 (11) , 572-577
An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma
Mulan Wei, Xujie Liu, Chunyu Cao, Jianlin Yang, Yafeng Lv, Jiaojiao Huang, Yanlin Wang & Ye Qin. BMB Reports 2018;51:572-7. https://doi.org/10.5483/BMBRep.2018.51.11.076
- 30 November 2018
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
- Vol. 51 (11) , 572-577
Open AccessAn engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma
Mulan Wei, Xujie Liu, Chunyu Cao, Jianlin Yang, Yafeng Lv, Jiaojiao Huang, Yanlin Wang & Ye Qin. BMB Reports 2018;51:572-7. https://doi.org/10.5483/BMBRep.2018.51.11.076
- 1 October 2010
- Published by Elsevier in Enzyme and Microbial Technology
- Vol. 47 (5) , 222-227
Production and optimization of recombinant human augmenter of liver regeneration by Pichia pastoris
- 1 October 2010
- Published by Elsevier in Enzyme and Microbial Technology
- Vol. 47 (5) , 222-227
Production and optimization of recombinant human augmenter of liver regeneration by Pichia pastoris